NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Thirumalai Chemicals' US subsidiary, TCL Specialties LLC, has commenced the first phase of commercial operations at its new manufacturing facility with the first sale of Maleic Anhydride (MAN). The facility features a MAN plant with a capacity of 40,500 tons per year and a food ingredients plant with over 30,000 tons per year capacity for Malic and Fumaric acid. The company expects the phased commissioning process to be fully stabilized during the first half of calendar year 2026. This expansion targets underserved markets in the North-Eastern and Mid-West US, providing a significant footprint in the North American specialty chemicals sector.
முக்கிய அம்சங்கள்
Commencement of first phase commercial operations with the first sale of Maleic Anhydride (MAN)Maleic Anhydride (MAN) plant capacity of approximately 40,500 tons per year (~90 million lbs/yr)Food ingredients plant capacity of over 30,000 tons per year for Malic acid and Fumaric acidPhased commissioning and stabilization expected to be completed during H1 of calendar year 2026Strategic entry into underserved North-Eastern and Mid-West US regional markets
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the US facility as it represents a major capacity addition and geographic diversification. The successful stabilization by H1 2026 could significantly boost the company's top-line and global market share in specialty chemicals.
Piramal Finance Appoints Shikha Sharma and 3 Others to Board with Over 99% Shareholder Approval
Piramal Finance Limited has announced the results of its postal ballot, confirming the appointment of four new directors to its board. Shareholders approved the appointment of Ms. Shikha Sharma as a Non-Executive Director and Ms. Anjali Bansal, Mr. Rajiv Mehrishi, and Mr. Asheet Lalit Mehta as Independent Directors. All resolutions were passed with a significant majority, exceeding 99.3% of the total votes polled. The inclusion of these experienced professionals is expected to strengthen the company's governance framework and strategic direction.
முக்கிய அம்சங்கள்
Ms. Shikha Sharma appointed as Non-Executive Director with 99.36% votes in favor.Ms. Anjali Bansal and Mr. Rajiv Mehrishi approved as Independent Directors with 99.37% support.Mr. Asheet Lalit Mehta appointed as Independent Director with 99.75% of votes in favor.Total voting turnout stood at 70.35% of the 226.68 million outstanding shares.
👀 கவனிக்க வேண்டியவை
The addition of high-caliber professionals to the board is a positive signal for corporate governance; investors should maintain their positions. Monitor how these strategic appointments influence the company's future growth and risk management policies.
Thirumalai Chemicals has successfully completed the allotment of 1,896,614 equity shares on a preferential basis to its promoter group at a price of ₹296 per share. This transaction has raised approximately ₹56.14 crores for the company, with the promoter group entity Ultramarine and Pigments Ltd contributing the bulk of the investment (₹45 crores). The allotment increases the company's total paid-up capital from 11.87 crore shares to 12.06 crore shares. This capital infusion by the promoters signals strong internal confidence in the company's long-term growth prospects.
முக்கிய அம்சங்கள்
Allotment of 1,896,614 equity shares of face value ₹1 each at an issue price of ₹296 per share.Total fundraise aggregates to ₹56,13,97,744 through a preferential issue to 16 promoter group entities.Ultramarine and Pigments Ltd emerged as the largest allottee, subscribing to 1,520,270 shares.Post-allotment, the company's paid-up capital has increased to ₹12,05,52,774 divided into 12.05 crore shares.
👀 கவனிக்க வேண்டியவை
Investors should take note of the promoter group's decision to infuse capital at ₹296 per share, which serves as a benchmark for valuation and a sign of management's commitment. Monitor the company's upcoming quarterly results to see how this additional capital is deployed for operational expansion.
Piramal Finance to sell 14.72% stake in Shriram Life Insurance for Rs 600 crore
Piramal Finance Limited has entered into a share purchase agreement to divest its entire 14.72% equity stake in Shriram Life Insurance Company Ltd (SLIC). The stake is being sold to Sanlam Emerging Markets (Mauritius) Limited for a total consideration of Rs 600 crore. This move is part of Piramal's strategic focus on monetizing non-core assets to strengthen its balance sheet. The transaction is expected to close by March 31, 2026, subject to IRDAI and other regulatory approvals.
முக்கிய அம்சங்கள்
Sale of 14.72% equity stake in Shriram Life Insurance for Rs 600 croreDivested asset contributed only 0.12% (Rs 12.68 crore) to FY25 revenue via dividendsTransaction expected to conclude in Q4 FY26 pending IRDAI approvalProceeds intended to strengthen the balance sheet and exit non-core investmentsBuyer is Sanlam Emerging Markets (Mauritius) Limited, part of the South African Sanlam Group
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive value-unlocking move that streamlines the company's focus on its core lending business. Monitor the timely receipt of regulatory approvals and the deployment of the Rs 600 crore cash inflow.
Piramal Finance Investor Presentation: AUM up 22% YoY to ₹91,447 Cr
Piramal Finance Limited has released an investor presentation highlighting its Q2 FY26 performance and strategic outlook. The company's consolidated AUM grew by 22% YoY to ₹91,447 Cr. Retail AUM now constitutes 82% of the total AUM. Consolidated PAT increased by 101% YoY to ₹327 Cr, while the growth business PBT reached ₹344 Cr, up 98% YoY. The company aims for RoAUM >3% with a target AUM-to-equity of 4.5-5.0x.
முக்கிய அம்சங்கள்
Consolidated AUM up 22% YoY to ₹91,447 CrRetail AUM constitutes 82% of total AUMConsolidated PAT up 101% YoY to ₹327 CrGrowth business PBT up 98% YoY to ₹344 CrLegacy AUM is ₹5,448 Cr, representing 6% of total AUM
👀 கவனிக்க வேண்டியவை
Review the investor presentation for detailed insights into Piramal Finance's strategy and financial performance. Monitor the company's progress towards achieving its RoAUM and AUM-to-equity targets.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Piramal Finance Investor Presentation on Investec AI Unmasked Conference
Piramal Finance Limited is presenting to investors at the 'Investec AI Unmasked - The Real & Possible Conference' on December 15, 2025. The investor presentation highlights the company's journey, tech approach, and AI integration. Piramal Finance's retail AUM has grown to ₹74,704 Cr, now representing 94% of the total AUM. The company has expanded its product portfolio to 13 products and has a presence in 429 cities across 26 states.
முக்கிய அம்சங்கள்
Retail AUM is ₹74,704 CrGrowth book is 94% of total AUMExpanded product portfolio to 13 products517 branches across the countryCross-sell contributes to 11% of all disbursements
👀 கவனிக்க வேண்டியவை
Review the investor presentation to understand Piramal Finance's growth strategy and AI initiatives. Monitor the company's progress in expanding its retail business and improving operational efficiency.
Thirumalai Chemicals' US Subsidiary Starts Pre-Commissioning of $255M West Virginia Facility
Thirumalai Chemicals' US subsidiary, TCL Specialties LLC, has commenced pre-commissioning and start-up activities at its new integrated manufacturing facility in West Virginia. The project, representing a $255 million investment, includes a 40,000 tons/yr Maleic Anhydride (MAN) plant and a 30,000 tons/yr Food Ingredients plant. The company expects the MAN unit to start by the end of 2025, with full stabilization of all units by H1 2026. To lead this expansion, industry veteran Vinod Tiwari has been appointed as CEO and Director of the US subsidiary.
முக்கிய அம்சங்கள்
Total investment of approximately $255 million in the West Virginia facility, funded via debt and equity.Facility includes a Maleic Anhydride plant (>40,000 tons/yr) and a Food Ingredients plant (>30,000 tons/yr).Strategic location in the Marcellus-Utica shale region provides a significant feedstock advantage for n-Butane.Phased startup planned with the MAN unit beginning by end of 2025 and full operations by H1 2026.Appointment of Vinod Tiwari, who has 40 years of global experience, as CEO of TCL Specialties LLC.
👀 கவனிக்க வேண்டியவை
Investors should track the successful commissioning of the MAN unit by late 2025, as this major expansion into the US market is a significant growth driver for the company's global revenue.
Piramal Finance Limited has received in-principle approval from stock exchanges for modifying the coupon rate of its Non-Convertible Debentures (NCDs) issued under ISINs INE516Y07014 and INE516Y07063. Approvals were granted by the National Stock Exchange of India on December 10, 2025, and BSE Limited on November 27, 2025. The company executed addenda to the Information Memorandum dated December 18, 2018, and March 8, 2019, respectively. Final listing will proceed upon receipt of modified ISIN letters from the Depositories.
முக்கிய அம்சங்கள்
Received in-principle approval for coupon rate modification on NCDsISINs affected: INE516Y07014 and INE516Y07063NSE approval date: December 10, 2025BSE approval date: November 27, 2025Addendum to Information Memorandum executed on December 11, 2025
👀 கவனிக்க வேண்டியவை
Investors holding NCDs under ISINs INE516Y07014 and INE516Y07063 should monitor the company's announcements regarding the final coupon rate and listing. Review the updated Information Memorandum for details.
Piramal Finance Denies Reports of Keertana Acquisition for Gold Loan Foray
Piramal Finance Limited has officially clarified to the National Stock Exchange that recent media reports regarding its interest in acquiring Keertana for a gold loan foray are factually incorrect. The company responded to a clarification request following an Economic Times article dated December 9, 2025. Management stated that there is no undisclosed material information pending that could impact price or volume behavior. The company maintains that recent equity share price movements are entirely market-driven and outside of management's control.
முக்கிய அம்சங்கள்
Categorically denied the news report published on December 9, 2025, regarding the Keertana acquisition.Confirmed that no material information or announcement is pending disclosure under SEBI Regulation 30.Attributed recent stock price and volume fluctuations to market forces rather than internal corporate developments.Reiterated commitment to ongoing compliance with SEBI Listing Regulations for all future material events.
👀 கவனிக்க வேண்டியவை
Investors should ignore the speculative acquisition rumors and focus on the company's official disclosures and quarterly financial performance.
TIRUMALCHM: Malaysia Unit Outage Prolonged; ₹235 Cr Revenue Impact
Thirumalai Chemicals' step-down subsidiary, Optimistic Organic Sdn Bhd (OOSB) in Malaysia, faces a prolonged outage of its Maleic Anhydride unit due to machinery failure. This is expected to reduce consolidated revenue by ₹235 Cr annually, representing 9.6% of FY25 consolidated revenue. The outage has already resulted in an approximate revenue reduction of ₹118 crore in H1 FY26. The Maleic Anhydride unit constituted about 4% (₹140 crore) of the consolidated net worth as at the end of FY25. The derivatives plant of OOSB continues to operate.
முக்கிய அம்சங்கள்
Maleic Anhydride unit outage expected to reduce consolidated revenue by ₹235 Cr annually.Maleic Anhydride business contributed about 9.6% of FY25 consolidated revenue.Outage resulted in approximately ₹118 crore reduction in revenue in H1 FY26.Maleic Anhydride unit constituted about ₹140 crore of the consolidated net worth as at end of FY25.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the progress of the repairs and the impact on Thirumalai Chemicals' consolidated financials. Consider the reduced revenue guidance when evaluating the company's future performance.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
